Jean Jacques Bienaime Purchases 1,000 Shares of Immunome (NASDAQ:IMNM) Stock

by · The Cerbat Gem

Immunome, Inc. (NASDAQ:IMNM – Get Free Report) Director Jean Jacques Bienaime acquired 1,000 shares of the business’s stock in a transaction on Wednesday, March 11th. The shares were purchased at an average cost of $21.55 per share, for a total transaction of $21,550.00. Following the completion of the acquisition, the director directly owned 38,415 shares in the company, valued at approximately $827,843.25. The trade was a 2.67% increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.

Immunome Price Performance

Shares of IMNM stock opened at $21.40 on Thursday. The firm has a 50-day moving average of $22.75 and a 200-day moving average of $17.97. The company has a market cap of $2.42 billion, a P/E ratio of -8.84 and a beta of 2.12. Immunome, Inc. has a one year low of $5.15 and a one year high of $27.65.

Immunome (NASDAQ:IMNM – Get Free Report) last released its quarterly earnings results on Tuesday, March 3rd. The company reported ($0.75) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.65) by ($0.10). Immunome had a negative net margin of 1,687.08% and a negative return on equity of 57.61%. As a group, research analysts expect that Immunome, Inc. will post -2.21 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of equities analysts have recently weighed in on the company. Craig Hallum boosted their target price on Immunome from $33.00 to $36.00 and gave the stock a “buy” rating in a research note on Wednesday, March 4th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Immunome in a research report on Thursday, January 22nd. Guggenheim lifted their price target on Immunome from $25.00 to $35.00 and gave the stock a “buy” rating in a report on Tuesday, December 16th. HC Wainwright assumed coverage on Immunome in a research report on Thursday, February 12th. They issued a “buy” rating and a $40.00 price objective on the stock. Finally, Evercore boosted their price objective on Immunome from $18.00 to $40.00 and gave the stock an “outperform” rating in a research report on Tuesday, December 16th. Ten investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $33.45.

Get Our Latest Report on IMNM

Institutional Investors Weigh In On Immunome

Large investors have recently added to or reduced their stakes in the company. Strs Ohio purchased a new stake in Immunome during the fourth quarter valued at about $64,000. Assetmark Inc. purchased a new position in shares of Immunome in the third quarter worth about $39,000. Aster Capital Management DIFC Ltd purchased a new position in shares of Immunome in the fourth quarter worth about $121,000. BIT Capital GmbH bought a new stake in shares of Immunome in the third quarter valued at approximately $69,000. Finally, BNP Paribas Financial Markets raised its position in shares of Immunome by 81.8% in the second quarter. BNP Paribas Financial Markets now owns 6,464 shares of the company’s stock valued at $60,000 after purchasing an additional 2,909 shares during the period. Hedge funds and other institutional investors own 44.58% of the company’s stock.

About Immunome

(Get Free Report)

Immunome, Inc is a clinical-stage biotechnology company focused on discovering and developing novel antibody-based therapeutics for oncology and infectious diseases. The company leverages a proprietary platform that mines the natural B-cell repertoire of patients with active disease to identify fully human monoclonal antibodies with unique mechanisms of action. Immunome’s approach is designed to uncover antibodies that engage the immune system in ways that traditional discovery methods may miss, enabling the development of therapies with potential for improved efficacy and safety profiles.

The company’s lead oncology program, IMM-BCP-01, is a multi-antibody cocktail currently in early-stage clinical trials targeting breast cancer antigens.

Read More